{"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"groups":[{"description":"Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria. After the end of treatment period, participants were allowed to enter long-term follow up period for up to 3 years for collection of subsequent AML treatment, EuroQol Group-5 Dimension-5 Level Instrument (EQ-5D-5L), remission status and survival (cause of death and date of death). Participants continuing to derive clinical benefit from gilteritinib as assessed by the investigator were allowed to continue the study treatment until a discontinuation criterion was met or if they had completed more than 3 years of treatment.","id":"BG000","title":"Gilteritinib"},{"description":"Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m\\^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on mitoxantrone, etoposide and intermediate-dose cytarabine (MEC) chemotherapy received mitoxantrone 8 mg/m\\^2 daily by IV for 5 days, etoposide 100 mg/m\\^2 daily by IV for 5 days and cytarabine 1000 mg/m\\^2 daily by IV for 5 days (days 1-5). Participants on fludarabine, cytarabine and granulocyte colony-stimulating factor with idarubicin (FLAG-IDA) chemotherapy received granulocyte-colony stimulating factor (G-CSF) 300 μg/m\\^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m\\^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m\\^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m\\^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15. After the end of treatment period, participants were allowed to enter the long-term follow-up period of up to 3 years for collection of subsequent AML treatment, EQ-5D-5L, remission status and survival (cause of death and date of death).","id":"BG001","title":"Salvage Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.6","value":"59"},{"groupId":"BG001","spread":"14.8","value":"57.6"},{"groupId":"BG002","spread":"14.7","value":"58.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"201"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"170"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"220"}],"title":"WHITE"},{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"102"}],"title":"ASIAN"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"21"}],"title":"BLACK OR AFRICAN AMERICAN"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"AMERICAN INDIAN OR ALASKA NATIVE"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}],"title":"UNKNOWN"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}],"title":"OTHER"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"}],"title":"MISSING"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"221"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"337"}],"title":"NOT HISPANIC OR LATINO"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"14"}],"title":"HISPANIC OR LATINO"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"UNKNOWN"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"15"}],"title":"MISSING"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"271"}],"title":"INTERMEDIATE"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"37"}],"title":"UNFAVORABLE"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"FAVORABLE"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"58"}],"title":"OTHER"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"description":"The category of \"Other\" includes those with cytogenetic risk status that cannot be categorized as favorable, intermediate or unfavorable.","paramType":"COUNT_OF_PARTICIPANTS","title":"Cytogenic Risk Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"311"}],"title":"0-1"},{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"60"}],"title":">=2"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"description":"ECOG performance status is a scale used to assess impact on daily activities. It is based on the investigator assessment. Scores range from 0 to 5, with 0-signifying fully active participant; 1-restricted in physically strenuous activity; 2-ambulatory and capable of all self-care, unable to work; 3-capable of only limited self-care, confined to bed more than 50% of waking hours; 4-completely disabled and 5-dead. Negative numerical score indicates an improvement and positive numerical score indicates a decline in participant's daily activities, indicating disease progression.","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Eastern Cooperative Oncology Group (ECOG)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"215"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"328"}],"title":"FLT3-ITD Alone"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"31"}],"title":"FLT3-TKD Alone"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"7"}],"title":"FLT3-ITD and FLT3-TKD"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"Others (Unknown/Missing/Negative)"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"FLT3 Mutation Status by Central Testing by FLT3 CDx","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"215"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"325"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"46"}],"title":"Yes"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"description":"Prior use of FLT3 inhibitor is defined as 'Yes' if participants received prior AML therapy of midostaurin, sorafenib or quizartinib; otherwise, prior use of FLT3 inhibitor is assigned as No.","paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Use of FLT3 Inhibitor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"166"}],"title":"NORTH AMERICA"},{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"111"}],"title":"EUROPE"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"94"}],"title":"ASIA"}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.281","value":"1.815"},{"groupId":"BG001","spread":"0.257","value":"1.777"},{"groupId":"BG002","spread":"0.272","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"321"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The analysis population was the ITT, with available data.","title":"Baseline Body Surface Area (BSA)","unitOfMeasure":"m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.31","value":"167.25"},{"groupId":"BG001","spread":"10.63","value":"166.39"},{"groupId":"BG002","spread":"10.41","value":"166.95"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"234"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"357"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The analysis population was the ITT, with available data.","title":"Baseline Height","unitOfMeasure":"centimeter (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"20.47","value":"72.79"},{"groupId":"BG001","spread":"19.73","value":"69.91"},{"groupId":"BG002","spread":"20.25","value":"71.82"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"367"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The analysis population was the ITT, with available data.","title":"Baseline Weight","unitOfMeasure":"kilogram (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"146"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Primary refractory without HSCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"101"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse within 6 months after CRc and no HSCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"51"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse after 6 months after CRc and no HSCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"48"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse within 6 months after allogeneic HSCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"25"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse after 6 months after allogeneic HSCT"}],"description":"Baseline stratification factors.","paramType":"COUNT_OF_PARTICIPANTS","title":"Response to First Line Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"224"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"High intensity chemotherapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"147"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Low intensity chemotherapy"}],"description":"Baseline stratification factors.","paramType":"COUNT_OF_PARTICIPANTS","title":"Preselected Salvage Chemotherapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"85"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Primary refractory w/o HSCT, high intensity (IT)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"61"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Primary refractory w/o HSCT, low IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"61"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse w/I 6 mths after CRc and no HSCT, high IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"40"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse w/I 6 mths after CRc and no HSCT low IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"34"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse after 6 mths after CRc and no HSCT high IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"25"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse w/I 6 mths after allogeneic HSCT low IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"23"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse w/I 6 mths after allogeneic HSCT high IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"21"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse after 6 mths after allogeneic HSCT high IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse after 6 mths after CRc and no HSCT low IT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"247"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"371"}],"units":"Participants"}],"title":"Relapse after 6 mths after allogeneic HSCT low IT"}],"description":"Baseline stratification factors. HSCT is hematopoietic stem cell transplant. CRc is composite complete remission.","paramType":"COUNT_OF_PARTICIPANTS","title":"Response to First Line Therapy-Preselected Salvage Chemotherapy","unitOfMeasure":"Participants"}],"populationDescription":"The analysis population was the Intention to Treatment (ITT), which consisted of all randomized participants."}